AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 292 min read$ROIV

Sukhatme Mayukh sold $34.1M of ROIV

Sukhatme Mayukh (President & CIO) sold 1,000,000 shares of Roivant Sciences Ltd. (ROIV) at an average of $34.10 ($34.08–$34.13, $34.10M total) across 2 trades over 2026-06-25 to 2026-06-26.

Original reporting
SEC EDGAR · Sukhatme Mayukh
Published Jun 29, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
medium confidence
Mentioned
$ROIV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

A large open-market sale by a top executive, reported without a 10b5-1 plan, may prompt traders to reassess short-term sentiment, though it provides no direct operational or financial guidance change.

02

Market read

Traders may treat the filing as a sentiment datapoint for ROIV, but without accompanying fundamentals it is unlikely to drive a durable repricing by itself.

03

What to watch

The article does not state tax/option-exercise context, total compensation, or whether other insiders sold/bought around the same time; those factors can change interpretation.

Relevance 7/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-29)

Background

The article is an SEC Form 4 insider transaction disclosure for Roivant Sciences Ltd., reported by its President & CIO.

Company-level read

Ticker impact

$ROIVBearishMedium confidence
Context

Roivant Sciences insider Sukhatme Mayukh sold 1,000,000 shares in open-market trades at ~$34.08–$34.13, per Form 4 filed today.

Expected impact

Likely modest negative bias for the stock around the filing window; magnitude depends on broader tape and whether other insiders/management offset.

Evidence & confidence

Form 4 provides a primary-source datapoint on insider selling size, timing (6/25–6/26), and absence of a pre-arranged 10b5-1 plan, but it does not indicate fundamentals or guidance changes.

Market effects

Sector

Limited sector read-through; this is company-specific insider activity rather than a sector catalyst.

Regional

No clear regional spillover implied by the filing alone.

Global

Minimal global relevance; disclosure is localized to Roivant’s insider transactions.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity/portfolio rebalancing and do not necessarily signal reduced confidence, especially when the sale is spread across two days.

Key entities

  • issuer
    Roivant Sciences Ltd.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Sukhatme Mayukh

    President & CIO who sold 1,000,000 shares at ~$34.08–$34.13.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min